Notice of Preliminary Results

Notice of Preliminary Results 

Oxford, UK - 4 April 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, will be announcing its preliminary results for the twelve months ended 31 December 2021 on Wednesday 20 April 2022. 

Roch Doliveux, Chair and Interim Chief Executive Officer, Stuart Paynter, Chief Financial Officer, and Kyriacos Mitrophanous, Chief Scientific Officer, will host a virtual briefing and Q&A session for analysts at 13.00 BST / 08.00 ET on the day of results. The presentation and webcast details will be made available on the Group's website at www.oxb.com. A replay webcast will be made available shortly afterwards.

-Ends-

Enquiries:

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: [email protected]

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: [email protected]

Mary-Jane Elliott / Matthew Neal

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group. In January 2022, Oxford Biomedica announced that it was broadening its leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as a 20% owner. To date, Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Boehringer Ingelheim, Beam Therapeutics, Arcellx, Cabaletta, Orchard Therapeutics and Santen, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people. Further information is available at www.oxb.com.